NeoImmuneTech
Yoonji Baek is a Drug Safety Scientist at NeoImmuneTech, where responsibilities include executing medical reviews of SAE reports for regulatory compliance and coordinating timely reporting of SUSARs to regulatory bodies such as the EMA and FDA. Previous experience as a pharmacist at CVS Health involved reviewing prescriptions, advising customers, and leading COVID-19 vaccine clinics. Baek held laboratory research assistant positions at Massachusetts General Hospital and Beth Israel Deaconess Medical Center, co-authoring scientific papers and conducting various lab experiments. Additional pharmacy internship experiences include roles at Joslin Diabetes Center and Cape Cod Healthcare, focusing on patient medication management and clinical research. Yoonji Baek holds a Doctor of Pharmacy (PharmD) degree from Massachusetts College of Pharmacy and Health Sciences.
NeoImmuneTech
NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases. Our lead drug candidate, NT-I7, is the only clinical-stage long acting rhIL-7, and is uniquely positioned to address unmet medical needs in Immuno-Oncology and Infectious Diseases such as COVID-19. IL-7 is a fundamental cytokine for lymphocyte development, survival, and memory development. Furthermore, NT-I7 has been shown clinically to have desired PK/PD and safety profiles, making it an ideal combination partner with T-cell targeted therapies as well as vaccines. NT-I7 is being studied in multiple clinical trials and many in collaboration with industry leaders in I-O, including Merck, BMS, and Roche for CPI combination trials. Follow us on Twitter @neoimmunetech